Metastatic Breast Cancer Therapy Effectiveness Gauged By Immunicon Kits
This article was originally published in The Gray Sheet
Executive Summary
Veridex is rolling out Immunicon's circulating tumor cell selection and enumeration IVD systems to roughly 20 U.S. comprehensive cancer centers and clinical labs
You may also be interested in...
CellSearch study
Counting circulating tumor cells with J&J/Veridex's cancer diagnostic system before treatment can independently predict progression-free survival and overall survival rates in patients with metastatic breast cancer, according to a 177-patient trial led by Massimo Cristofanilli, MD, University of Texas, published in the Aug. 19 NEJM. The CellSearch system was 510(k) cleared in June and likely will be commercially available this fall, according to Veridex...
Immunicon IPO Proceeds To Support FDA Clearance Of Cancer Diagnostics
Johnson & Johnson/Veridex will stand to benefit from Immunicon's proposed $70.9 mil. IPO under the terms of the companies' exclusive development, licensing and marketing agreement for cancer diagnostics
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.